MBII has been the topic of a number of other reports. Jefferies Group LLC reiterated a hold rating and issued a $2.50 price objective on shares of Marrone Bio Innovations in a research report on Tuesday, May 2nd. Zacks Investment Research upgraded Marrone Bio Innovations from a sell rating to a hold rating in a research report on Wednesday, January 18th.
Shares of Marrone Bio Innovations (NASDAQ:MBII) traded down 3.74% during mid-day trading on Friday, reaching $1.03. 105,568 shares of the company’s stock traded hands. The company has a 50 day moving average of $1.29 and a 200 day moving average of $1.89. The company’s market cap is $32.29 million. Marrone Bio Innovations has a 12 month low of $0.71 and a 12 month high of $2.79.
Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Wednesday, March 29th. The basic materials company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.06. The firm had revenue of $2.69 million during the quarter. Analysts expect that Marrone Bio Innovations will post ($0.92) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Marrone Bio Innovations’ (MBII) Buy Rating Reiterated at HC Wainwright” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/06/17/marrone-bio-innovations-inc-mbii-rating-reiterated-by-hc-wainwright-updated-updated-updated.html.
In related news, major shareholder Ardsley Advisory Partners acquired 50,000 shares of the stock in a transaction on Tuesday, April 25th. The stock was acquired at an average price of $1.72 per share, for a total transaction of $86,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.25% of the stock is currently owned by insiders.
An institutional investor recently bought a new position in Marrone Bio Innovations stock. Ardsley Advisory Partners acquired a new stake in Marrone Bio Innovations, Inc. (NASDAQ:MBII) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 774,438 shares of the basic materials company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned approximately 3.15% of Marrone Bio Innovations as of its most recent SEC filing. Institutional investors and hedge funds own 29.47% of the company’s stock.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
What are top analysts saying about Marrone Bio Innovations Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Marrone Bio Innovations Inc. and related companies.